



#17
Decl. w/
attach
10/30/02

PATENT

Docket No. 377882000800

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 042148943 US Date of Deposit: October 23, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Box AF, Assistant Commissioner for Patents, Washington, D.C. 20231.

Diane Blevins
Diane Blevins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Gary VAN NEST, et al.

Serial No.: 09/642,492

Filing Date: August 18, 2000

For: METHODS OF MODULATING AN
IMMUNE RESPONSE USING
IMMUNOSTIMULATORY
SEQUENCES AND COMPOSITIONS
FOR USE THEREIN

Examiner: S. Foley

Group Art Unit: 1648

RECEIVED

OCT 29 2002

TECH CENTER 1600/2900

**DECLARATION OF GARY VAN NEST, PH.D.
PURSUANT TO 37 C.F.R. § 1.132**

Box AF
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

I, Gary Van Nest, Ph.D., declare as follows:

1. I currently reside at 639 Skyline Drive, Martinez, California 94553.
2. I am an inventor named in the above-referenced patent application, and am familiar with the written communication from the Patent Office dated April 23, 2002.
3. Described herein are additional results from experiments, performed by me or under my direction, which are from controls performed along with the experiments described in Example 1 in the patent specification. These results support the difference in the immune

response to an antigen (*i.e.*, second antigen) following the claimed method (administration of (i) an ISS-containing polynucleotide in proximate association with a first antigen and (ii) a second antigen) from the immune response to the antigen (*i.e.*, second antigen) following the control method (administration of (i) an ISS-containing polynucleotide and (ii) the antigen (*i.e.*, second antigen)).

4. As described in Example 1 on page 50 of the specification, sets of mice were immunized with either 1 μ g β gal, 1 μ g β gal mixed with 1 μ g AIC or 1 μ g β gal mixed with 10 μ g AIC. AIC denotes a conjugate of the antigen Amb a 1 and ISS-containing polynucleotide of SEQ ID NO:1. In addition to what is described in Example 1 of the specification, control sets of mice were immunized intradermally three times at two-week intervals with either 1 μ g β gal mixed with 1 μ g ISS or 1 μ g β gal mixed with 10 μ g ISS (admixture controls). Two weeks after the second and third immunizations, β gal-specific IgG1 and IgG2a responses were determined by ELISA as described in Example 1. Four weeks after the third immunization, mice were sacrificed, and spleen cell IFN γ and IL-5 responses to β gal were determined by ELISA as described in Example 1.

5. The results of this experiment with 1 μ g β gal, 1 μ g β gal mixed with 1 μ g AIC, and 1 μ g β gal mixed with 10 μ g AIC are presented in Figure 1 and Tables 2 and 3 of the specification. The results of the admixture controls of this experiment with 1 μ g β gal mixed with 1 μ g ISS and with 1 μ g β gal mixed with 10 μ g ISS are herein presented in Exhibits A and B. The experimental data presented in the specification was calculated as arithmetic means as compared to the experimental data presented in Exhibits A and B which was calculated as geometric means.

6. After both the second and third immunizations, the antibody response to immunization with β gal alone was predominantly an IgG1 response, consistent with a Th2 response. Administration of β gal in an admixture with 1 or 10 μ g of ISS-containing polynucleotide (admixture controls) resulted in a shift in the immune response away from a Th2 response and toward a Th1 response (Exhibit A). Co-administration of one or ten μ g AIC (the ISS-containing polynucleotide linked to the antigen Amb a 1) with β gal modulated the β gal-specific immune response compared to the administration of β gal mixed with an ISS-containing polynucleotide (Exhibit A) and modulated the β gal-specific immune response compared to the

administration of β gal alone (specification, Figure 1 and Table 2). For example, modulation of a Th1 immune response was demonstrated by the increased IgG2a response to β gal after the second immunization with AIC as compared to the IgG2a response seen with β gal alone and as compared to the IgG2a response seen with β gal mixed with an ISS (admixture control) as depicted in Exhibit A.


7. As depicted in Table 3 of the specification and in Exhibit B, spleen cells from mice immunized with β gal alone secreted a relatively low level of IFN γ and a relatively high level of IL-5 in response to β gal. These cytokine responses are indicative of a Th2 response, consistent with the antibody responses discussed above. Administration of β gal in an admixture with 1 or 10 μ g of ISS-containing polynucleotide resulted in a shift in the immune response away from a Th2 response and toward a Th1 response as indicated by an increased IFN γ and a decreased IL-5 in response to β gal (Exhibit B). Co-administration of β gal with 1 or 10 μ g of AIC increased the IFN γ response and decreased the IL-5 response in response to β gal by the spleen cells (specification Table 3), again demonstrating a modulation of an immune response to β gal when the β gal is administered with AIC as compared to when the β gal is administered with an ISS-containing polynucleotide.

8. The data from this experiment, presented herein and in Example 1, demonstrate the difference in the immune response to an antigen (β gal) when administered with an ISS-containing polynucleotide (ISS) and when administered with an ISS-containing polynucleotide in proximate association with a different antigen (AIC). These admixture control results support the discovery that administration of a second antigen with an ISS-containing polynucleotide in proximate association to a first antigen results in a modulation of an immune response to the second antigen.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.


October 22, 2002

Date



Gary Van Nest

Anti- β gal Antibody Responses of Mice Co-administration of β gal with ISS or AIC



Anti- β gal Cytokine Responses of Mice Co-administration of β gal with ISS or AIC

EXHIBIT B

